Page 106 - 《中国药房》2025年18期
P. 106

[ 2 ]  SCHINOCCA C,RIZZO C,FASANO S,et al.Role of the   [15]  TILLACK C,EHMANN L M,FRIEDRICH M,et al.Anti-
               IL-23/IL-17  pathway  in  rheumatic  diseases:an  overview  TNF  antibody-induced  psoriasiform  skin  lesions  in  pa‐
               [J].Front Immunol,2021,12:637829.                   tients  with  inflammatory  bowel  disease  are  characterised
          [ 3 ]  张瀚予,罗娟,董明志,等 . 英夫利西单抗及维得利珠单                       by  interferon- γ -expressing  Th1  cells  and  IL-17A/IL-22-
               抗治疗中重度溃疡性结肠炎的回顾性队列研究[J].昆明                          expressing  Th17  cells  and  respond  to  anti-IL-12/IL-23
               医科大学学报,2024,45(10):36-44.                           antibody treatment[J].Gut,2014,63(4):567-577.
          [ 4 ]  张才英,蒋雪生 . 英夫利西单抗注射剂治疗强直性脊柱                   [16]  LI  S  J,PEREZ-CHADA  L  M,MEROLA  J  F. TNF
               炎的临床研究[J]. 中国临床药理学杂志,2017,33(1):                    inhibitor-induced  psoriasis:proposed  algorithm  for  treat‐
               21-24.                                              ment  and  management[J]. J  Psoriasis  Psoriatic  Arthritis,
          [ 5 ]  VAN  VOLLENHOVEN  R,TAKEUCHI  T,PANGAN A          2019,4(2):70-80.
               L,et al.Efficacy and safety of upadacitinib monotherapy   [17]  LITTMAN D R,RUDENSKY A Y.Th17 and regulatory T
               in methotrexate-naive patients with moderately-to-severely   cells  in  mediating  and  restraining  inflammation[J]. Cell,
               active  rheumatoid  arthritis(SELECT-EARLY):a  multi‐  2010,140(6):845-858.
               center,multi-country,randomized,double-blind,active   [18]  OLTEANU R,ZOTA A.Paradoxical reactions induced by
               comparator-controlled trial[J].Arthritis Rheumatol,2020,  tumor necrosis factor-alpha antagonists:a literature review
               72(10):1607-1620.                                   based on 46 cases[J].Indian J Dermatol Venereol Leprol,
          [ 6 ]  GUERRA  I,PÉREZ-JELDRES  T,IBORRA  M,et  al.       2016,82(1):7-12.
               Incidence,clinical characteristics,and management of pso‐  [19]  刘明伟,彭慧,冷晓杰.英夫利西单抗治疗重度斑块状银
               riasis induced by anti-TNF therapy in patients with inflam‐  屑病的临床疗效及其对PD-1和PD-L1表达水平的影响
               matory  bowel  disease:a  nationwide  cohort  study[J].         [J].临床和实验医学杂志,2022,21(24):2660-2664.
               Inflamm Bowel Dis,2016,22(4):894-901.          [20]  ZIPPI M,PICA R,DE NITTO D,et al.Biological therapy
          [ 7 ]  徐梦骏,郑敏.银屑病生物制剂治疗与炎症性肠病[J].皮                       for dermatological manifestations of inflammatory bowel
               肤科学通报,2020,37(5):477-479.                           disease[J].World J Clin Cases,2013,1(2):74-78.
          [ 8 ]  SAGONAS I,ILIOPOULOS G,BARALIAKOS X,et al.   [21]  单芳芳.TNF-α拮抗剂诱发或加重银屑病的临床特征与
               Anti-TNF-α induced paradoxical psoriasis in patients with   处理[D].苏州:苏州大学,2019.
               ankylosing  spondylitis:a  systematic  review[J]. Clin  Exp   [22]  WOLLINA U,HANSEL G,KOCH A,et al.Tumor necro‐
               Rheumatol,2024,42(1):178-184.                       sis factor-alpha inhibitor-induced psoriasis or psoriasiform
          [ 9 ]  陈静静,钱佩佩,曹凯等.我国药品不良反应关联性评价                         exanthemata:first 120 cases from the literature including
               方法与诺氏评估量表法的对比与分析[J]. 中国药事,                          a series of six new patients[J].Am J Clin Dermatol,2008,9
               2020,34(8):988-992.                                (1):1-14.
          [10]  CICCARELLI F,DE MARTINIS M,SIRUFO M M,et al.  [23]  许馨文,周群燕,陈中霞,等 . 生物制剂治疗中重度溃疡
               Psoriasis  induced  by  anti-tumor  necrosis  factor  alpha   性 结 肠 炎 的 研 究 进 展 [J]. 胃 肠 病 学 ,2021,26(6):
               agents:a  comprehensive  review  of  the  literature[J]. Acta   363-367.
               Dermatovenerol Croat,2016,24(3):169-174.       [24]  MARITS  P,LANDUCCI  L,SUNDIN  U,et  al. Trough
          [11]  何梓阳,陈信生 . 英夫利西单抗诱发脓疱性银屑病一例                         s-infliximab and antibodies towards infliximab in a cohort
               [J].实用皮肤病学杂志,2021,14(4):244-246.                    of 79 IBD patients with maintenance infliximab treatment
          [12]  游晓炎,郑盈盈,王宪英 . 基于 FAERS 数据库的英夫利                     [J].J Crohns Colitis,2014,8(8):881-889.
               西单抗不良事件信号挖掘分析[J].中国药物警戒,2024,                  [25]  PROTIC  M,SCHOEPFER  A,YAWALKAR  N,et  al.
               21(3):335-340.                                      Development  of  psoriasis  in  IBD  patients  under  TNF-
          [13]  GARCOVICH S,DE SIMONE C,GENOVESE G,et al.          antagonist  therapy  is  associated  neither  with  anti-TNF-
               Paradoxical  skin  reactions  to  biologics  in  patients  with   antagonist antibodies nor trough levels[J]. Scand J Gastroen-
               rheumatologic disorders[J].Front Pharmacol,2019,10:282.  terol,2016,51(12):1482-1488.
          [14]  XIE W H,XIAO S Y,HUANG H,et al. Incidence of and   [26]  谭书法,张磊昌,高强强,等 . 生物制剂和小分子药物治
               risk factors for paradoxical psoriasis or psoriasiform lesions   疗溃疡性结肠炎有效性与安全性的网状 Meta 分析[J].
               in inflammatory bowel disease patients receiving anti-TNF   中国全科医学,2024,27(17):2155-2166.
               therapy:systematic  review  with  meta-analysis[J]. Front    (收稿日期:2025-04-08  修回日期:2025-08-27)
               Immunol,2022,13:847160.                                                            (编辑:陈 宏)




          · 2316 ·    China Pharmacy  2025 Vol. 36  No. 18                            中国药房  2025年第36卷第18期
   101   102   103   104   105   106   107   108   109   110   111